Sotirios Tsimikas, MD, of the University of California San Diego, talks with DocWire News about experimental agents that lower lipoprotein(a) [LP(a)], a genetic risk factor for atherosclerotic cardiovascular disease in patients with established cardiovascular disease (CVD).
In this interview, he discusses results from his recent phase II, placebo-controlled study, in patients with high levels of Lp(a), treated with AKCEA-APO(a)-LRx, as well as other potential PCSK9 inhibitors such as evolocumab. The objective of the phase 2 trial was to determine the optimal dose and regimen of AKCEA-APO(a)-LRx for further clinical development. The trial was randomized, double-blind, placebo-controlled, dose-ranging trial designed to test the safety and efficacy of AKCEA-APO(a)-LRx injected subcutaneously. It included 286 CVD patients randomized (5:1) to 5 parallel cohorts treated with 5 different dosing regimens. Patients were treated for at lest 6 months, with a primary efficacy endpoint of percent change in Lp(a) from baseline.
Click the image to watch the full interview for the discussion of the results.
To read more DocWire News coverage of AHA 2018, click here.
To read more cardiology news, click here.